RESTON, Va.–(BUSINESS WIRE)–Vital Metrix, Inc. today announced that MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market, has selected the company as the winner of its “Best Biometric Sensor Solution” award in the 2019 MedTech Breakthrough Awards program.
Vital Metrix, Inc. is developing a patented data analysis solution to enable rapid and reliable non-invasive measurement of cardiac flow and pressure parameters for physician offices and hospitals. After receiving FDA clearance, the Vital Metrix technology will enable physicians and staff to access this vital information and improve the care of patients living with congestive heart failure. Adoption of Vital Metrix will enable clinicians to frequently evaluate and adjust treatment, which can lead to more cost-effective heart failure management.
“Congestive heart failure remains one of the most challenging and deadliest health challenges in America today, and improved cardiac output measurement can make huge strides in taking on this challenge,” said James Johnson, managing director, MedTech Breakthrough. “Vital Metrix’s work to develop a non-invasive, periodic or continuous, cost effective cardiac output measurement in the clinical setting is a breakthrough innovation that we are excited to recognize in our annual MedTech Breakthrough Awards program.”
The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records, mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,500 nominations from over 15 countries.
“We are honored to receive the MedTech Breakthrough award. It reinforces our vision that frequent, non-invasive monitoring of heart failure patients is a key element of better management of this chronic disease that impacts millions of Americans, and millions around the world,” said Alton Reich, Vital Metrix founder and CEO. “The Vital Metrix team has spent almost 10 years developing this technology with the goal of helping patients and clinicians.”
Vital Metrix combines a non-invasive measurement of pulse pressure, the waveform captured by a pulse oximeter, and patented advanced signal processing to quickly measure cardiac output and other cardiac parameters from patients.
Following FDA clearance, the Vital Metrix measurement will be performed quickly with easy-to-use sensors which are: a pulse oximeter and blood pressure cuff. The data will be sent to Vital Metrix’s HIPAA-compliant servers, where the patented algorithm will process the raw data into actionable information that can be used by physicians/clinicians to adjust treatment for their patients.
About Vital Metrix
Vital Metrix, Inc. develops a heart monitor that provides data to cardiologists while patients are home. The company offers Vital Metrix, a portable non-invasive cardiac output measurement device that uses digital signal processing based on pulse oximetry. Its device provides data to a patient’s cardiologist while the patient is home, improves treatment of congestive heart failure and quality of life, and potentially reduces the risk of hospital readmission.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.
Contacts
Ginny Rowland
801.361.9809
growland@tech2mark.com
Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…
Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…
New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…
Data presented at the 2024 FMF (Fetal Medicine Foundation) World Congress in Lisbon, Portugal shows the…
Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…
GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…